Glycogen synthase kinase-3 is an unusual protein serine/threonine kinase that, unlike most of its 500-odd relatives in the genome, is active under resting conditions and is inactivated upon cell stimulation. The two mammalian isoforms, GSK-3α and β, play largely overlapping roles and have been implicated in a variety of human pathologies, including Type II diabetes, Alzheimer's disease, bipolar disorder and cancer. Recently, the modes of regulation of this enzyme have been elucidated through a combination of structural and cell biological studies. A series of relatively selective small molecules have facilitated chemical manipulation of the enzyme in intact cells and tissues, and new roles for the protein kinase in embryonic stem cell differentiation and motility have emerged. Despite these advances, the therapeutic value of this enzyme as a drug target remains clouded by uncertainty over the potential of antagonists to promote tumorigenesis. This article describes the state of understanding of this intriguing enzyme, and weighs current evidence regarding whether there is a therapeutic window for amelioration of diseases in which it is implicated, in the absence of inducing new pathologies.
Metabolic regulation
Glycogen synthase kinase-3 (GSK-3) was originally identified as one of several protein kinases capable of phosphorylating the rate-limiting enzyme of glycogen deposition, GS (glycogen synthase) [1] . In peripheral tissues, insulin modulates glycogen metabolism through a co-ordinated increase in glucose transport and glycogen synthesis. Insulin stimulates glycogen synthesis by activating GS through dephosphorylation of GS, particularly at the sites targeted by GSK-3 [2] . This action of insulin is mediated by simultaneously inhibiting GSK-3 kinase activity and by activating one of the glycogen-associated forms of protein phosphatase 1. While the identity of the specific phosphatase and the mechanism by which it is activated by insulin remains elusive, the signalling pathway by which insulin inhibits GSK-3 has now been established. It was first shown that, in rat adipocytes, insulin treatment rapidly inactivated a protein kinase that was capable of phosphorylating ATP-citrate lyase, and it was later found that this protein kinase was GSK-3α [3, 4] . Subsequently, it was shown that the insulin-mediated inhibition of both isoforms of GSK-3 (α and β) was mediated through a phosphorylation-dependent mechanism, with the phosphorylation of each isoform occurring at a serine (S) residue in the N-terminal lobe of the protein kinase (S21 for GSK-3α and S9 for GSK-3β) [5] . Several protein kinases can phosphorylate these residues, namely the AGC kinases, p70 ribosomal S6 kinase, p90 ribosomal S6 kinase, protein kinase A and protein kinase C. However, insulinmediated phosphorylation and inhibition of GSK-3 in vivo is primarily mediated through activation of the PI3K (phosphoinositide 3-kinase)/PKB (protein kinase B) pathway [5, 6] . The degree of inhibition of GSK-3 activity by insulin in skeletal muscle is ≈50%.
The mechanism by which N-terminal serine phosphorylation inhibits GSK-3 activity relates to an unusual property of GSK-3 in phosphorylating its substrates. The minimal recognition motif for phosphorylation by GSK-3 is S/ TXXXS/T(P), where 'X' is any amino acid, and '(P)' denotes the phosphorylatable residue. In order for GSK-3 to efficiently phosphorylate its substrate proteins, it requires that the substrate is previously phosphorylated (by another protein kinase) at a serine or threonine residue located four residues C-terminal (underlined in consensus motif) to the site of GSK-3 phosphorylation (S/T residue in bold) [7] .
Through biochemical and structural studies, it was demonstrated that the N-terminus of GSK-3, the structure of which is relatively disordered in resting cells, upon phosphorylation at S9, folds back on itself, forming electrostatic interactions with several residues (including R96) that are involved in binding the priming phosphate (Figure 1 ). This conformation occludes the active site, preventing binding of primed substrates. Thus N-terminal serine phosphorylation acts as a 'pseudosubstrate' competitive inhibitor [8] [9] [10] . Therefore it appears that GSK-3 exists in a constitutively active conformation in resting cells, and that inhibition of GSK-3 activity (through serine phosphorylation) is a means by which extracellular stimuli regulate this protein kinase. (A), and pseudosubstrate inactivation of GSK-3 (B) (A) GSK-3 preferentially phosphorylates substrates that are pre-phosphorylated by a priming kinase. For example, in the case of the GSK-3 substrate β-catenin, phosphorylation by CKI on S45 primes it for sequential phosphorylation on T41, S37 and S33 by GSK-3. (B) Pseudosubstrate inactivation of GSK-3. The N-termini of GSK-3α and β contain serine residues (S21 and S9 respectively) that, when phosphorylated by an inhibitory kinase, serve as primed pseudosubstrates that can occupy the substrate binding pocket of GSK-3, inhibiting its activity towards true substrates.
However, as described below, there are additional means of regulating GSK-3 activity distinct from phosphorylation (e.g. subcellular localization, binding to scaffold proteins, etc.).
In addition to its role in glycogen metabolism, GSK-3 also modulates other metabolic processes, including the rate of protein synthesis. eIF2B (eukaryotic initiation factor 2B) is a guanine nucleotide-exchange factor that is important for initiation of translation. Phosphorylation of eIF2B by GSK-3 inhibits its guanine-nucleotide exchange activity. This effect, like that of GS, is reversed by insulin through the PI3K/PKBdependent inhibition of GSK-3 and dephosphorylation of eIF2B, leading to the activation of protein synthesis (Figure 2 ) [11] .
Diabetes
Type II diabetes mellitus (T2DM) is a serious metabolic disorder that is characterized by the inability to respond to the hormone insulin (insulin resistance), as well as the failure of the pancreatic β cells to compensate for insulin resistance by increasing insulin secretion. These two defects lead to the loss of control of glucose homoeostasis, resulting in hyperglycaemia and further complications, such as kidney nephropathy and blindness. T2DM is a rapidly growing problem, and its worldwide frequency is projected to rise by 6% per year.
Glucose/insulin-clamp studies, muscle biopsies/cell culture and NMR analyses have revealed that one of the major features of T2DM is the impairment of both basal-and insulin-stimulated glucose metabolism in peripheral tissues (i.e. skeletal muscle and liver). Compared with normal tissues, the muscle tissue from Type II diabetic patients has reduced glycogen deposition that is correlated with decreased activity of GS and impaired responsiveness to insulin [12, 13] .
While there is, as yet, no evidence for genetic mutations in the two GSK-3 genes associated with the pathogenesis of T2DM [14] , there are studies demonstrating increased protein levels as well as activity of GSK-3 in skeletal muscle of Type II diabetics, and in adipose tissues of obese diabetic mice [15, 16] . GSK-3 has also been implicated as a negative regulator of insulin signalling through serine phosphorylation of IRS-1 (insulin receptor substrate-1), making it a poorer substrate for tyrosine phosphorylation by the insulin receptor, thereby attenuating insulin signalling [17] .
Consequently, the therapeutic potential of GSK-3 inhibitors has become a major area of pharmaceutical interest. Indeed, there are several classes of inhibitors that are reportedly selective for GSK-3. Only a few of these GSK-3 inhibitors have been utilized in examining the role of GSK-3 in metabolism, and they are described below.
Lithium chloride is a widely used inhibitor of GSK-3 in vitro and in vivo, and has been shown to have some insulinmimetic properties in various cell types. For instance, lithium chloride stimulates glucose transport and glycogen synthesis in adipocyte and muscle cell lines [18, 19] . SB 216763 and SB 415286 are cell-permeant maleimide compounds developed by GlaxoSmithKline that selectively inhibit GSK-3 [20] . Treatment of liver cells, L6 muscle cells and adipocytes with these compounds stimulates glycogen synthesis [20, 21] . All three compounds also mimic insulin's ability to regulate hepatic gene transcription, namely the repression of PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase), rate-limiting enzymes of gluconeogenesis [22] .
Based on these observations, studies of GSK-3 inhibitors have recently been extended into rodent models of diabetes and Rhesus monkeys. Chiron has developed several potent and specific inhibitors of GSK-3. CHIR98014, CHIR98023 and CHIR99021 are aminopyrimidine derivatives that, in cultured human muscle cells and hepatocytes, stimulate the activation of GS and glycogen synthesis [23, 24] . Oral administration of these compounds in Zucker diabetic (fa/fa) rats reduced overall glucose and insulin concentrations in an oral glucose-tolerance test, demonstrating an improvement in glucose disposal. This is accompanied by stimulation of GS in both the muscle and liver, with a significant increase in liver glycogen synthesis. Inhibition of gluconeogenesis was also evident, as demonstrated by the reduction in fasting glucose levels in response to an overnight treatment of rats with the inhibitor, possibly reflecting its ability to suppress hepatic expression of PEPCK and G6Pase [25] . Since these exciting findings, Chiron has developed improved derivatives of the GSK-3 inhibitors that have not only been characterized in the ZDF rats or ob/ob mice, but also in 'non-leptin/leptin receptor-defective' diabetic rodents, as well as diabetic Rhesus monkeys [26] . The binding of insulin to its cell-surface receptor triggers the recruitment and activation of PI3K. At the plasma membrane, PI3K stimulates the formation of PtdIns(3,4,5)P 3 , which triggers the co-localization of phosphoinositide-dependent kinase 1 (PDK1) and PKB, allowing PDK1 to activate PKB. Upon activation, PKB phosphorylates and inactivates GSK-3, resulting in the dephosphorylation of glycogen synthase and eIF2B, two substrates of GSK-3 that control the rates of glycogen metabolism and protein synthesis respectively.
Wnt signalling: the other occupation of GSK-3
The Wnts, a family of secreted glycoprotein ligands, are essential for proper embryonic development due to their role in the regulation of cellular proliferation, differentiation, motility and polarity [27] . One way that Wnts can mediate a response is through the stabilization of a specific pool of β-catenin that is usually targeted for degradation. Stabilization of this β-catenin results in its accumulation in the cytosol and ultimately the nucleus, where it binds architectural transcription factors of the TCF/LEF family to activate transcription of Wnt target genes [28] . GSK-3 plays a central role in this canonical Wnt signal transduction pathway, since its phosphorylation of β-catenin on key residues is required for β-catenin's ubiquitination and proteasomal degradation in 'resting' cells ( Figure 3) . Conversely, upon Wnt treatment, GSK-3 must be prevented from phosphorylating β-catenin to bypass the β-catenin degradation machinery.
Phosphorylation of β-catenin by GSK-3 occurs in a multiprotein complex containing, in part, axin, APC (adenomatous polyposis coli) and β-catenin [29] . Mutations in axin, APC and β-catenin have been linked to numerous types of human cancer, including those of the breast, skin, liver and colon [30] . Although once thought to be one of the few unprimed substrates for GSK-3, β-catenin has been shown to be primed at S45 by CKI (casein kinase I), allowing efficient subsequent serial phosphorylations by GSK-3 on residues T41, S37 and S33 [31] . It is the phosphorylation of β-catenin on S33 and S37 that appears to be essential for β-catenin's recognition by the ubiquitin ligase β-TrCP, which targets it for subsequent degradation [32] . Mutations of β-catenin at the residues phosphorylated by CKI or GSK-3 sites have been found in numerous types of cancer, including colorectal cancer, melanoma, pilomatricoma and hepatocellular and ovarian carcinoma [30] . Although it has been proposed that regulated phosphorylation of S45 by CKI might serve as a switch to modulate β-catenin's degradation [33] , a In unstimulated cells, a minimal complex of GSK-3, axin, APC and β-catenin is required for GSK-3-mediated phosphorylation of β-catenin which targets it for ubiquitination and degradation. Wnt stimulation activates the receptor Frizzled and co-receptor LRP5/6, which then signal through Dishevelled, using an unclear mechanism, to inactivate β-catenin phosphorylation.
Unphosphorylated β-catenin accumulates and translocates to the nucleus, where it transactivates genes regulated by TCF/LEF transcription factors. recent study in Drosophila cells strongly suggests that the phosphorylation status of this residue does not change upon wingless (wg; the Drosophila Wnt orthologue) stimulation [34] . Similar findings have been found in mouse ESCs (embryonic stem cells), in which both isoforms of GSK-3 have been 'knocked out'. These cells have a massive increase in cytoplasmic and nuclear β-catenin that remains phosphorylated on S45 regardless of treatment with Wnt-3a and is unphosphorylated on residues 33, 37 and 41 as expected (B. Doble and J. Woodgett, unpublished work).
Axin and APC are also GSK-3 substrates. The phosphorylation of axin by GSK-3 has been reported to increase axin's stability and affinity for β-catenin [35] [36] [37] . It has been proposed that the mechanism of β-catenin stabilization in Wnt signalling might depend more on the regulation of axin stability rather than that of β-catenin itself, since it appears that axin might be the limiting factor regulating β-catenin degradation [38] . The phosphorylation of APC by GSK-3 also increases APC binding to β-catenin (Figure 3 ) [39] .
The Wnt-induced mechanism precluding GSK-3's phosphorylation of β-catenin remains elusive. Wnt treatment of human embryonic kidney-293 cells, which was effective in stabilizing β-catenin, caused a reduction in GSK-3 activity as measured by immunoprecipitating endogenous GSK-3 and assaying its activity in vitro [40] . This reduction in activity was not as a result of S9/21 phosphorylation. Insulin treatment, although causing a reduction in GSK-3 activity and increasing S9 phosphorylation, did not affect β-catenin levels in the same cells. Thus it appears that the GSK-3 involved in β-catenin regulation is 'insulated' from other signalling pathways and is regulated in a unique manner. Recent experiments using Drosophila cells came to the same conclusions as the HEK-293 studies: namely, that wg treatment sufficient to stabilize armadillo (Drosophila β-catenin orthologue) does not result in S9 phosphorylation of the Drosophila GSK-3 orthologue, shaggy (sgg)/Zeste-white3, and that insulinmediated inactivation of sgg through S9 phosphorylation does not impact on armadillo levels [34, 41] . Further underscoring that S9 phosphorylation is not essential for wg signalling, a sgg minigene with an S9A mutation is able to rescue mutant sgg in developing larvae without developmental anomalies [41] . In a mammalian cell system, mouse ESCs re-expressing an S21A mutant form of GSK-3α in a GSK-3 null background have normalized cytosolic β-catenin levels compared with the very high levels in the null cells, and respond to Wnt3A with increased cytosolic β-catenin (B. Doble and J. Woodgett, unpublished work).
Recently, Sato et al. [42] reported that a small molecule inhibitor of GSK-3, BIO (bromo-indirubin-3 -oxime), could maintain the pluripotentiality of ESCs of mouse and human origin. The BIO effect on pluripotency is suggested to be due to increased Wnt signalling resulting from GSK-3 inhibition. That the effect is specific to inhibition of GSK-3 is supported by work with mouse ESCs totally lacking GSK-3, which are extremely limited in their differentiation potential (B. Doble et al., in preparation). These findings are perhaps not surprising, since it has been shown that increased Wnt signalling appears to favour self-renewal in other types of stem cells, including haematopoietic stem cells and mammary progenitor cells, and that mouse ESCs with mutations in APC are also unable to differentiate properly [43] [44] [45] . It has been suggested that Wnt's role in stem-cell maintenance and selfrenewal may explain why mutations in Wnt pathway proteins are found frequently in certain types of cancer [46] .
GSK-3 as a therapeutic target
Preliminary data from the GSK-3 inhibitor programmes (carried out as short-and long-term administrations) demonstrate that these compounds can reduce hyperglycaemia and improve insulin sensitivity [26] . While this proof-of-principle in inhibiting GSK-3 as a means to relieve the effects of T2DM is very promising, there are serious concerns regarding the potential of GSK-3 inhibitors as therapeutics. Firstly, the specificity of these compounds is not restricted to GSK-3. For example, lithium has many other effects, inhibiting adenylate cyclase, inositol monophosphatase as well as activating JNK [47] [48] [49] . SB 216763, SB 415286 and the Chiron inhibitors have been classed as more selective inhibitors of GSK-3, as they have been shown not to affect the activity of 24 other protein kinases in vitro. However, this does not prove complete specificity and many inhibitors of this class tend to exhibit some activity against the cyclin-dependent kinases.
Secondly, and more importantly, from a therapeutic standpoint GSK-3 is also a key player in the Wnt signalling pathway, which is dysregulated in many human cancers. GSK-3 inhibitors would be expected to mimic Wnt action, potentially promoting oncogenesis (see the Wnt signalling section). Indeed, all of these compounds have been shown to elevate the levels of β-catenin in various cell lines. Despite this, no deleterious effects of these compounds have been formally demonstrated as yet in the diabetic rodent studies. While there are some indications that the Chiron inhibitors elevate β-catenin levels in mice (as mentioned in the Material and methods section of [24] ), the relative induction compared with Wnt was not determined. One will have to assess the effects of long-term exposure of the GSK-3 inhibitors on the incidence of tumours. However, it is possible that mild inhibition of GSK-3 (≈30-40%) is sufficient for therapeutic insulin-resensitization of the muscle and liver tissues in T2DM, and that a much stronger degree of inactivation (>75%) of GSK-3 may be required to invoke growthpromoting effects. This is supported by the finding that β-catenin levels are largely unaffected in embryos that lack GSK-3β [50] , and that disruption of at least three of the four GSK-3 alleles is necessary to begin to impact β-catenin in ESCs (B. Doble et al., in preparation).
